(3Z)-3-[(3,4-dimethylanilino)methylidene]-1H-indol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3Z)-3-[(3,4-dimethylanilino)methylidene]-1H-indol-2-one
• 化学式: C₁₇H₁₆N₂O
• 分子量: 264.32
• InChiKey: JLIKDYPTKYBPLE-GDNBJRDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
  申请人：——

  公开号：US20030199478A1

  公开（公告）日：2003-10-23

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调控、调节和/或抑制异常细胞增殖。
• 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
  申请人：——

  公开号：US20030225152A1

  公开（公告）日：2003-12-04

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调制和/或抑制异常细胞增殖。
• 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
  申请人：Andrews W. Steven

  公开号：US20060025413A1

  公开（公告）日：2006-02-02

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调节和/或抑制异常细胞增殖。
• 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
  申请人：Andrews W. Steven

  公开号：US20060063940A1

  公开（公告）日：2006-03-23

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。
• TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS
  申请人：Mackerell, JR. Alexander

  公开号：US20120190708A1

  公开（公告）日：2012-07-26

  The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.

  多重耐药病原体的出现需要寻找作用于先前未被开发的靶标的新抗生素。Nicotinate单核苷酸腺苷转移酶（NadD家族），是大多数细菌NAD生物合成的必需酶，被选为基于结构的抑制剂开发的目标。为此，发明人已经鉴定出小分子化合物，通过与酶上的新型抑制性结合位点相互作用来抑制细菌靶标酶，而对功能相当的人类酶没有影响。